Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
View MissionIR's Instablogs on:
  • Continental Stock Transfer & Trust Company Offers Services At A Value No Other Major Transfer Agent Can Match

    The services required of a good stock transfer agent are many and varied, and can be especially distinctive when involving the unique needs of emerging companies. Continental Stocks Transfer & Trust Company has worked for many years to bring large company services to the emerging business market. The company continues to win awards for client satisfaction and affordable services:

    As the only major transfer agent specializing in smaller to midsize emerging and growth companies, Continental goes out of its way to provide truly customized and responsive business solutions, including 24/7 access to senior-level experts.

    Taking a company public is obviously a critical milestone in a company's business history, and Continental's initial public offering (NYSEARCA:IPO) experts have managed hundreds of offerings. As a result, they know what going public really takes, and the importance of acting proactively to create the best customer experience.

    Coordinating the IPO and post-IPO activity of a Special Purpose Acquisition Company (SPAC) is a particular area of Continental expertise. They've handled virtually all of the SPACs brought to market since 1990, with a total value of over $15 billion in raised funds.

    Continental's ControlBook Reporting lets clients access data when and where it is needed, using a client-based online tool that allows access to Share Controls for every class of stock on-demand.

    A successful annual meeting involves a large number of tasks, many of which are required by state and federal law and require planning and execution throughout the year. Continental's dedicated annual meeting and proxy specialists draw on their industry experience and knowledge to assist and support all such activities, before, during, and after the annual meeting.

    Continental experts stay on top of the numerous and changing complex rules and regulations issued by the U.S. Securities and Exchange Commission (SEC), and are thoroughly familiar with SEC compliance for the necessary filing of SEC-required forms.

    Shareholders can expect first-class attention and accurate stock plan administration. Continental is able to deliver efficiencies and shareholder satisfaction at an exceptional value.

    For more information, visit ContinentalStock.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Feb 21 1:48 PM | Link | Comment!
  • Hanwha SolarOne Co., Ltd. (HSOL) Among First To Secure Coveted New ISO 14067 Carbon Footprint Certification For PV Solar Modules

    Hanwha SolarOne, the flagship company for South Korean business enterprise giant Hanwha Group and one of the top ten PV (photovoltaic) solar module manufacturers on earth, known throughout the industry for their high-quality units and competitively low prices, was proud to announce today that they are one of the first PV module manufacturers to have their product certified under the new internationally recognized carbon emission lifecycle quantification standard, ISO 14067.

    Issued by German safety standards authority and global certification, technical and safety services provider, TUV Rheinland last month, the certificates represent an extremely robust new measuring stick for PV modules and even contains a "from cradle to factory-gate" assessment protocol for supply chain products, making this new carbon footprint assessment measure extremely accurate. For maximum granularity in dealing with such varied product groups as the standard must account for, a Product Category Rules schema was developed and it should be noted that HSOL's certified polycrystalline HSL 60 Poly and HSL 72 Poly modules were classed as crystalline solar cells under the rules.

    Senior Director of Products and Marketing for HSOL, Winfried Wahl, emphasized the significance of this new and highly stringent certification for a market where tenders and green certificates are such important drivers, citing the great care standard developers put in to crafting this new benchmark, designed for accurately documenting levels of greenhouse gas emissions. Wahl went on to say firmly that a standardized and internationally accepted benchmark certification framework like ISO 14067 was absolutely essential when it comes to truly rationalizing the PV market product space along environmental lines, again showing the immense pride HSOL has earned in helping to advance overall sector transparency by being at the tip of the spear in compliance innovation.

    Such transparency is indeed critical in the solar PV module market and the new standard should quickly shake out HSOL's less worthy competitors in short order. Clearly, this new standard bolsters the presence of established players like HSOL and with a sizeable business already firmly founded spanning EU and NA markets, as well as Africa, the Middle East and South America, Hanwha SolarOne can now expect to see considerably more consumer activity in the space funneled their way as a result of their shrewd move to satisfy the new standard with more top-of-the-line products. HSOL continues making big strides across all segments as well just on strength of product alone, from residential and commercial, to government entities and utilities, their high-efficiency polycrystalline modules are prized for a compact layout, 3-busbar cell design which reduces current loss and improves overall output (the current doesn't have to travel as far). The cells are encapsulated in some of the highest quality EVA (ethylene-vinyl-acetate) around, sourced directly (and periodically quality control checked to ensure it meets the company's own exacting standards) from one of the world's most widely regarded EVA producers and the aluminum alloy frames are corrosion-resistant oxidation coated, with field tested 660 lbs plus load strength on the durable glass surfacing per square meter.

    For more on Hanwha SolarOne Co., Ltd. visit Hanwha-SolarOne.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Tags: HSOL
    Feb 21 1:47 PM | Link | Comment!
  • Pluristem Therapeutics, Inc. (PSTI) Applies For Orphan Drug Designation For PLX Cells To Treat Preeclampsia

    Leading placenta-based cell therapies developer Pluristem Therapeutics announced it is submitting its application to the FDA to request Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for treating severe preeclampsia.

    Receiving Orphan Drug Designation can qualify a company for various benefits under the Orphan Drug Act of 1983 (ODA), as amended, including a seven-year period of orphan drug exclusivity upon approval of the product, a tax credit for certain clinical testing expenses for the orphan drug, written guidance on the nonclinical and clinical studies necessary for obtaining market approval of an orphan drug, and orphan drug grants.

    Pluristem recently established a preeclampsia steering committee featuring key medical opinion leaders, and this Orphan Drug application submission is an important step for the company in advancing its preeclampsia development program. The great unmet medical need for preeclampsia makes this indication one of the company's top priorities. Pluristem looks forward to advancing into human trials and is hopeful that strong preclinical data for PLX cells will lead to similar findings at the clinical level.

    Orphan Drug Designation has been successfully received by Pluristem for PLX cells in two other indications: treatment of aplastic anemia and treatment of Buerger's disease.

    For more information about Pluristem, visit pluristem.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Tags: PSTI
    Feb 21 1:46 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.